Table 2.

Distribution of methylation levels in ATMmvp2a, ATMmvp2b, and LINE1 in breast cancer cases and controls

ControlCaseControlCase
AssayStudynanaMedian (IQR)Median (IQR)Pb
ATMmvp2aBGS24824976.4 (70.2–80.2)76.8 (70.9–82.7)0.02
EPIC28323576.1 (70.5–80.6)75.7 (70.0–80.8)0.40
KConFab21015676.9 (71.6–81.5)81.8 (75.8–86.5)4.87 × 10−6
ATMmvp2bBGS23424891.0 (87.0–94.8)91.4 (85.6–95.0)0.61
EPIC28724092.2 (87.3–95.2)92.3 (88.3–95.7)0.36
KConFab20816292.6 (87.2–96.3)92.3 (82.4–96.5)0.24
LINE1BGS24224179.0 (77.9–80.1)79.0 (78.1–79.9)0.96
EPIC26323275.1 (73.9–76.3)75.2 (73.9–76.3)0.89
KConFab21815376.0 (74.3–78.0)76.6 (75.2–77.6)0.20

NOTE: Bold signifies P < 0.05.

Abbreviation: IQR, interquartile range.

  • aDifferences in numbers of cases and controls within each study with total numbers are due to missing data (failed quality control) on methylation markers.

  • bWilcoxon matched pairs test for BGS and EPIC and Mann–Whitney U test for KConFab.